Background/clinical characteristics by treatment group
| Active TMS (n=10) | Inactive TMS (n=11) | |
| SAPAS-SR total scores (median, IQR) | 3 (2–4.8) | 3 (2–4) |
| NART estimated IQ scores (median, IQR) | 107 (105–113) | 108 (108–112) |
| Psychiatric comorbidity present (baseline) (n, %) | 6 (60) | 5 (45.5) |
| Other FND symptoms (baseline) (n, %) | 5 (50) | 9 (81.8) |
| Age at FND onset, years (median, IQR) | 35 (28.25–45) | 31 (23.5–48.5) |
| Duration of FND, months (baseline) (median, IQR) | 41 (14.75–63) | 42 (37–107.5) |
| Duration since FND diagnosis, months (baseline) (median, IQR) | 1 (0–5.25) | 12 (0.5–38.5) |
| Number of current medications (median, IQR) | ||
| Baseline | 3 (2.25–11) | 4 (3.5–6) |
| TMS session 1 | 3 (2–11) | 4 (3.5–6.5) |
| TMS session 2 | 7 (2.25–12.5) | 4.5 (3.25–6.5) |
| Follow-up | 3 (2–12) | 5 (3.5–7) |
| Concurrent treatments (n, %) | ||
| Baseline | 10 (100) | 10 (100) |
| TMS session 1 | 10 (100) | 9 (100) |
| TMS session 2 | 6 (100) | 8 (100) |
| Follow-up | 9 (100) | 9 (100) |
FND, functional neurological disorder; IQ, intelligence quotient; IQR, interquartile range; NART, National Adult Reading Test; SAPAS-SR, Standardised Assessment of Personality Abbreviated Scale–Self-Report; TMS, transcranial magnetic stimulation.